This decrease in tumor burden extended to a survival advantage in 4H11-CCR2b (median survival of 70 days) treated mice compared to 4H11 (median survival of 58.5 days) and 4H11-CCR5 (median survival of 54 days) (Figure 4C). Here, CCR5 is linked to neoplasm.